Ç×¾ÏÄ¡·á¸¦ À§ÇØ »ç¿ëµÈ Ç¥ÇǼºÀåÀÎÀÚ ¼ö¿ëü ¾ïÁ¦Á¦·Î À¯¹ßµÈ ±ä¼Ó´«½çÁõ 2¿¹
Paradoxical Trichomegaly of the Eyelashes During Treatment with EGFR Inhibitors: 2 Case Report
´ëÇѾȰúÇÐȸÁö 2014³â 55±Ç 6È£ p.908 ~ p.912
³ª°ÇÈÄ(Na kun-Hoo) - °í·Á´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
¾ö¿µ¼·(Eom Young-Sub) - °í·Á´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
°¼ö¿¬(Kang Su-Yeon) - °í·Á´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
±èÈ¿¸í(Kim Hyo-Myung) - °í·Á´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
¼ÛÁ¾¼®(Song Jong-Suk) - °í·Á´ëÇб³ Àǰú´ëÇÐ ¾È°úÇб³½Ç
Abstract
¸ñÀû: Æó¾ÏÀÇ Ç×¾ÏÄ¡·á·Î Ç¥ÇǼºÀåÀÎÀÚ ¼ö¿ëü ¾ïÁ¦Á¦¸¦ º¹¿ëÇϰí Àִ ȯÀÚ¿¡¼ ¹ß»ýÇÑ ±ä¼Ó´«½çÁõ 2¿¹¸¦ º¸°íÇϰíÀÚ ÇÑ´Ù.
Áõ·Ê¿ä¾à: ù ¹øÂ° Áõ·Ê´Â 82¼¼ ¿©ÀÚ È¯ÀÚ·Î ¾ç¾ÈÀÇ ÅëÁõÀ» ÁÖ¼Ò·Î ³»¿øÇÏ¿´´Ù. ȯÀÚ´Â ÀüÀ̼º Æó¾ÏÀ¸·Î Áø´Ü¹Þ°í 6°³¿ù ÀüºÎÅÍ gefitinib (Iressa¢ç, AstraZeneca, London, UK)À» º¹¿ëÇϰí ÀÖ¾úÀ¸¸ç, ¾È°ú °Ë»ç¿¡¼ ¼Ó´«½çÀÌ ºñÁ¤»óÀûÀ¸·Î ±æ¾îÁ® ÀÖ¾ú°í, °á¸·ÃæÇ÷ °ú °¢¸·»óÇǹ̶õÀÌ °üÂûµÇ¾ú´Ù. µÎ ¹øÂ° Áõ·Ê´Â 52¼¼ ³²ÀÚ È¯ÀÚ·Î ºñ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î Áø´Ü¹Þ°í 7°³¿ù ÀüºÎÅÍ erlotinib (Tarceva¢ç OSI Pharmaceuticals, Inc., Melville, NY, USA)À» º¹¿ëÇϰí ÀÖ¾ú´Ù. ¾ç¾ÈÀÇ ½ÉÇÑ ÃæÇ÷°ú À̹°°¨À» ÁּҷΠóÀ½ ³»¿øÇÏ¿´À» ¶§ ¼Ó´«½çÀÇ Æ¯º°ÇÑ º¯È¸¦ º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª 3°³¿ù ÈÄ¿¡´Â ¼Ó´«½çÀÌ ºñÁ¤»óÀûÀ¸·Î ±æ¾îÁ® ÀÖ¾ú°í ±¸ºÎ·¯Áø ÇüŸ¦ º¸¿´´Ù.
°á·Ð: Ç×¾ÏÄ¡·á ¿µ¿ª¿¡¼ Ç¥ÇǼºÀåÀÎÀÚ ¼ö¿ëü ¾ïÁ¦Á¦ÀÇ »ç¿ëÀº Áõ°¡Çϰí ÀÖÀ¸¸ç À̵éÀÌ ÀÏÀ¸Å³ ¼ö ÀÖ´Â ±ä¼Ó´«½çÁõ µî ¾È°úÀû ºÎÀÛ¿ë¿¡ ´ëÇÏ¿© ÁÖÁöÇÒ Çʿ䰡 ÀÖ´Ù.
Purpose: To introduce 2 cases of trichomegaly associated with the use of systemic epidermal growth factor receptor (EGFR) inhibitors for the treatment of lung cancer.
Case summary: An 82?year?old female visited our clinic for ocular pain in both eyes. She was suffering from metastatic lung cancer and was under daily treatment with gefitinib (Iressa¢ç, AstraZeneca, London, UK) for 6 months. On ophthalmologic examination, she presented with abnormally elongated eyelashes, hyperemic conjunctiva and dense corneal erosion. A 52?year?old male who was diagnosed with non?small cell lung cancer 7 months before and treated with erlotinib (Tarceva¢ç OSI Pharmaceuticals, Inc., Melville, NY, USA) was referred to our clinic for injection and foreign body sensation in both eyes. Although there were no remarkable changes in eyelashes at the initial visit, long, curly, uneven eyelashes were observed after 3 months.
Conclusions: Due to the increased use of EGFR inhibitors in anti?cancer treatment, ophthalmologists should be aware of these chemotherapeutics¡¯ adverse effects.
Ű¿öµå
Epidermal growth factor receptor inhibitor, Trichomegaly
KMID :
0360220140550060908
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)